JP2021504465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504465A5 JP2021504465A5 JP2020545877A JP2020545877A JP2021504465A5 JP 2021504465 A5 JP2021504465 A5 JP 2021504465A5 JP 2020545877 A JP2020545877 A JP 2020545877A JP 2020545877 A JP2020545877 A JP 2020545877A JP 2021504465 A5 JP2021504465 A5 JP 2021504465A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- population
- fetal
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 28
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 230000001605 fetal effect Effects 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003471 mutagenic agent Substances 0.000 claims 8
- 231100000707 mutagenic chemical Toxicity 0.000 claims 8
- 230000003505 mutagenic effect Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 210000000604 fetal stem cell Anatomy 0.000 claims 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 150000004982 aromatic amines Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000002962 chemical mutagen Substances 0.000 claims 2
- 230000009615 deamination Effects 0.000 claims 2
- 238000006481 deamination reaction Methods 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000002703 mutagenesis Methods 0.000 claims 2
- 231100000350 mutagenesis Toxicity 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims 1
- 108060000255 AIM2 Proteins 0.000 claims 1
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 claims 1
- 108010036280 Aquaporin 4 Proteins 0.000 claims 1
- 102000012002 Aquaporin 4 Human genes 0.000 claims 1
- 102000004000 Aurora Kinase A Human genes 0.000 claims 1
- 108090000461 Aurora Kinase A Proteins 0.000 claims 1
- 102100023054 Band 4.1-like protein 4A Human genes 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100024485 Cell division cycle-associated protein 7 Human genes 0.000 claims 1
- 101710092479 Centrosomal protein of 55 kDa Proteins 0.000 claims 1
- 102100031219 Centrosomal protein of 55 kDa Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100027419 Cytochrome P450 4B1 Human genes 0.000 claims 1
- 101700026669 DACH1 Proteins 0.000 claims 1
- 102100028735 Dachshund homolog 1 Human genes 0.000 claims 1
- 102100031539 E3 ubiquitin-protein ligase RNF144B Human genes 0.000 claims 1
- 102100024739 E3 ubiquitin-protein ligase UHRF1 Human genes 0.000 claims 1
- 102100033176 Epithelial membrane protein 2 Human genes 0.000 claims 1
- 102100037156 Gap junction beta-2 protein Human genes 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 claims 1
- 101001049968 Homo sapiens Band 4.1-like protein 4A Proteins 0.000 claims 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 claims 1
- 101000980893 Homo sapiens Cell division cycle-associated protein 7 Proteins 0.000 claims 1
- 101001130266 Homo sapiens E3 ubiquitin-protein ligase RNF144B Proteins 0.000 claims 1
- 101000760417 Homo sapiens E3 ubiquitin-protein ligase UHRF1 Proteins 0.000 claims 1
- 101000851002 Homo sapiens Epithelial membrane protein 2 Proteins 0.000 claims 1
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 claims 1
- 101000995194 Homo sapiens Nebulette Proteins 0.000 claims 1
- 101001111328 Homo sapiens Nuclear factor 1 A-type Proteins 0.000 claims 1
- 101001071236 Homo sapiens PHD finger protein 19 Proteins 0.000 claims 1
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 claims 1
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 claims 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 1
- 102100034431 Nebulette Human genes 0.000 claims 1
- 102100024006 Nuclear factor 1 A-type Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100036870 PHD finger protein 19 Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229950008805 abexinostat Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- 229960003094 belinostat Drugs 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 108010018719 cytochrome P-450 CYP4B1 Proteins 0.000 claims 1
- 230000009849 deactivation Effects 0.000 claims 1
- 230000032459 dedifferentiation Effects 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002308 embryonic cell Anatomy 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 229950005837 entinostat Drugs 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229950007812 mocetinostat Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 210000002220 organoid Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023144329A JP2024000006A (ja) | 2017-11-24 | 2023-09-06 | ガンを処置するための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306635.8 | 2017-11-24 | ||
| EP17306635 | 2017-11-24 | ||
| PCT/EP2018/082429 WO2019101956A1 (en) | 2017-11-24 | 2018-11-23 | Methods and compositions for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023144329A Division JP2024000006A (ja) | 2017-11-24 | 2023-09-06 | ガンを処置するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504465A JP2021504465A (ja) | 2021-02-15 |
| JP2021504465A5 true JP2021504465A5 (enExample) | 2022-01-06 |
| JP7408036B2 JP7408036B2 (ja) | 2024-01-05 |
Family
ID=60627577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545877A Active JP7408036B2 (ja) | 2017-11-24 | 2018-11-23 | ガンを処置するための方法及び組成物 |
| JP2023144329A Pending JP2024000006A (ja) | 2017-11-24 | 2023-09-06 | ガンを処置するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023144329A Pending JP2024000006A (ja) | 2017-11-24 | 2023-09-06 | ガンを処置するための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11679148B2 (enExample) |
| EP (1) | EP3713596A1 (enExample) |
| JP (2) | JP7408036B2 (enExample) |
| KR (2) | KR102752418B1 (enExample) |
| CN (1) | CN111670043A (enExample) |
| AU (2) | AU2018371212B2 (enExample) |
| CA (1) | CA3083158A1 (enExample) |
| IL (2) | IL314506A (enExample) |
| WO (1) | WO2019101956A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| CN112703011A (zh) | 2018-08-06 | 2021-04-23 | 国家医疗保健研究所 | 用于治疗癌症的方法和组合物 |
| CN110609141A (zh) * | 2019-09-30 | 2019-12-24 | 中山大学孙逸仙纪念医院 | Gltscr1前列腺癌预后检测试剂及其试剂盒 |
| CN113061656A (zh) * | 2021-03-25 | 2021-07-02 | 南京先声医学检验有限公司 | Tet1基因突变在预测结肠癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| CN113144181B (zh) * | 2021-04-20 | 2022-07-19 | 徐州医科大学 | 一种靶向b7h3的dna疫苗、制备方法及应用 |
| US20220347349A1 (en) * | 2021-04-30 | 2022-11-03 | Stemcellago Inc. | Engineered cartilage |
| CN114774359B (zh) * | 2022-03-24 | 2022-11-08 | 中山大学附属第一医院 | 一种宫颈鳞癌类器官培养基及其构建方法 |
| CN120384042B (zh) * | 2024-01-29 | 2025-11-28 | 北京大学第一医院(北京大学第一临床医学院) | 一种优化人多潜能干细胞来源肾脏类器官的重组蛋白制剂 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4806476A (en) | 1983-09-08 | 1989-02-21 | Lovelace Medical Foundation | Efficient cell fusion process |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| JP2740320B2 (ja) | 1988-08-04 | 1998-04-15 | アムラド・コーポレイション・リミテッド | 胚幹細胞のインビトロ増殖 |
| US5240840A (en) | 1991-04-05 | 1993-08-31 | Regents Of The University Of Michigan | Dna superfragment cloning |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| JP3314241B2 (ja) | 1992-04-06 | 2002-08-12 | ヤマハ発動機株式会社 | 自動二輪車用エンジンの排気浄化装置 |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| US5728868A (en) | 1993-07-15 | 1998-03-17 | Cancer Research Campaign Technology Limited | Prodrugs of protein tyrosine kinase inhibitors |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| ES2174250T5 (es) | 1996-04-12 | 2010-04-21 | Warner-Lambert Company Llc | Inhibidores irreversibles de tirosina quinasas. |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| WO1999020741A1 (en) | 1997-10-23 | 1999-04-29 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2376957A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| CA2376951A1 (en) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Src kinase inhibitor compounds |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| CA2384101A1 (en) | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GEP20053530B (en) | 1999-10-19 | 2005-05-25 | Merck & Co Inc | Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001028993A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| NL1017973C2 (nl) | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
| US6921632B2 (en) | 2000-08-30 | 2005-07-26 | Maria Biotech Co., Ltd. | Human embryonic stem cells derived from frozen-thawed embryo |
| WO2002097090A1 (en) | 2001-05-31 | 2002-12-05 | Sumitomo Pharmaceuticals Co., Ltd. | Genes with es cell-specific expression |
| EP1404672B1 (en) | 2001-06-22 | 2006-01-18 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6927293B2 (en) | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7592177B2 (en) | 2003-11-10 | 2009-09-22 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP5346925B2 (ja) | 2008-05-02 | 2013-11-20 | 国立大学法人京都大学 | 核初期化方法 |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011148983A1 (ja) | 2010-05-25 | 2011-12-01 | 独立行政法人国立がん研究センター | 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US9637732B2 (en) | 2010-11-04 | 2017-05-02 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| CA2829607A1 (en) | 2011-03-11 | 2012-09-20 | Mcmaster University | A method of vaccination comprising a histone deacetylase inhibitor |
| US20130136722A1 (en) | 2011-11-11 | 2013-05-30 | The Board Of Trustees Of The University Of Illinois | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts |
| KR101467631B1 (ko) * | 2012-05-22 | 2014-12-05 | 가톨릭대학교 산학협력단 | 자살 유전자 치료법에서의 발프로산의 기능 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3209382B1 (en) | 2014-10-24 | 2020-11-25 | Calidi Biotherapeutics, Inc. | Combination immunotherapy approach for treatment of cancer |
| AU2014277667B2 (en) * | 2014-12-15 | 2022-07-14 | The University Of Queensland | Differentiation of pluripotent stem cells to form renal organoids |
| WO2017027757A2 (en) | 2015-08-11 | 2017-02-16 | StemImmune, Incorporated | Smallpox vaccine for cancer treatment |
| CN116376812A (zh) | 2016-05-25 | 2023-07-04 | 国家医疗保健研究所 | 治疗癌症的方法和组合物 |
| US20180296850A1 (en) | 2017-04-14 | 2018-10-18 | Tianxin Wang | Reagents and methods for cancer treatment using Magnetic particle |
-
2018
- 2018-11-23 AU AU2018371212A patent/AU2018371212B2/en active Active
- 2018-11-23 EP EP18811197.5A patent/EP3713596A1/en active Pending
- 2018-11-23 KR KR1020207018295A patent/KR102752418B1/ko active Active
- 2018-11-23 KR KR1020257000260A patent/KR20250008153A/ko active Pending
- 2018-11-23 JP JP2020545877A patent/JP7408036B2/ja active Active
- 2018-11-23 CN CN201880087466.6A patent/CN111670043A/zh active Pending
- 2018-11-23 IL IL314506A patent/IL314506A/en unknown
- 2018-11-23 US US16/766,438 patent/US11679148B2/en active Active
- 2018-11-23 CA CA3083158A patent/CA3083158A1/en active Pending
- 2018-11-23 IL IL274837A patent/IL274837B2/en unknown
- 2018-11-23 WO PCT/EP2018/082429 patent/WO2019101956A1/en not_active Ceased
-
2023
- 2023-06-09 US US18/207,752 patent/US12403110B2/en active Active
- 2023-09-06 JP JP2023144329A patent/JP2024000006A/ja active Pending
-
2025
- 2025-07-07 AU AU2025205174A patent/AU2025205174A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504465A5 (enExample) | ||
| JP2019516754A5 (enExample) | ||
| Gilgenkrantz et al. | Understanding liver regeneration: from mechanisms to regenerative medicine | |
| Schirrmacher | From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment | |
| Bose et al. | Treatment of relapsed/refractory acute myeloid leukemia | |
| KR102501827B1 (ko) | 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼 | |
| RU2018141200A (ru) | Способы и композиции для лечения опухолей | |
| Wefers et al. | Immune curbing of cancer stem cells by CTLs directed to NANOG | |
| KR102752418B1 (ko) | 암 치료를 위한 방법 및 조성물 | |
| JP6949336B2 (ja) | 人工多能性幹細胞由来腸管幹細胞の維持培養 | |
| AU2017210031A1 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| JP2019524667A (ja) | 養子細胞移入と腫瘍溶解性ウイルスの併用療法 | |
| Mavroudi et al. | Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy | |
| WO2019184459A1 (zh) | 溶瘤病毒疫苗和过继性免疫细胞联合疗法 | |
| JP2022130675A (ja) | メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬 | |
| Hemmings | The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis | |
| Letafati et al. | Oncolytic viruses against cancer, promising or delusion? | |
| Sinkovics | Will the Human Cerebral Cortex Subdue the Oncogenome? | |
| Yu et al. | The C-terminus domain of the hepatitis B virus x protein stimulates the proliferation of mouse foetal hepatic progenitor cells, although it is not required for the formation of spheroids | |
| Burchett et al. | A universal boosting strategy for adoptive T cell therapy using a paired vaccine/chimeric antigen receptor | |
| Torres-Montaner | Cancer origin in committed versus stem cells: hypothetical antineoplastic mechanism/s associated with stem cells | |
| Vicente-Dueñas et al. | Therapeutic Targeting of the Myeloma Stem Cell. | |
| Mitchell et al. | Immunosenescence and the 3Rs: Restoration, Replacement and Reprogramming: Immunosenescence and Its Correction | |
| Yu | Investigation of a novel experimental therapeutic involving transcriptional reprogramming of invasive cancer cells with" stem-like" characteristics | |
| HK40050731A (en) | Improved targeted t-cell therapy |